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Background: Glucose-6-phosphate dehydrogenase (G6PD, EC 1.1.1.49) deficiency is caused by one or more
mutations in the G6PD gene on chromosome X. An association between enzyme levels and gene haplotypes
remains to be established.
Methods: In this study, we determined G6PD enzyme levels and sequenced the coding region, including the
intron-exon boundaries, in a group of individuals (163 males and 86 females) who were referred to the clinic with
suspected G6PD deficiency. The sequence data were analysed by physical linkage analysis and PHASE haplotype
reconstruction.
Results: All previously reported G6PD missense changes, including the AURES, MEDITERRANEAN, A-, SIBARI,
VIANGCHAN and ANANT, were identified in our cohort. The AURES mutation (p.Ile48Thr) was the most common
variant in the cohort (30% in males patients) followed by the Mediterranean variant (p.Ser188Phe) detectable in
17.79% in male patients. Variant forms of the A- mutation (p.Val68Met, p.Asn126Asp or a combination of both) were
detectable in 15.33% of the male patients. However, unique to this study, several of such mutations co-existed in
the same patient as shown by physical linkage in males or PHASE haplotype reconstruction in females. Based on 6
non-synonymous variants of G6PD, 13 different haplotypes (13 in males, 8 in females) were identified. Five of these
were previously unreported (Jeddah A, B, C, D and E) and were defined by previously unreported combinations of
extant mutations where patients harbouring these haplotypes exhibited severe G6PD deficiency.
Conclusions: Our findings will help design a focused population screening approach and provide better
management for G6PD deficiency patients.
Keywords: Glucose-6-phosphate dehydrogenase, Haemolytic anaemia, DNA sequencing, Haplotype, PHASE
reconstruction, Linkage analysis, Gene mutationBackground
The G6PD gene encodes the enzyme glucose-6-phosphate
dehydrogenase (G6PD, EC 1.1.1.49). The enzyme is involved
in the normal processing of carbohydrates and plays a critical
role in red blood cells. It is responsible for the first step in
the pentose phosphate cycle, a pathway that converts glucose
to ribose-5-phosphate, which is the building block of purines
and pyrimidines. G6PD catalyses the production of NADPH,* Correspondence: w.z.kafienah@bristol.ac.uk
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reproduction in any medium, provided the orwhich plays a major role in protecting cells from potentially
harmful reactive oxygen species.
G6PD deficiency is the most common human metabolic
inborn error affecting more than 400 million people
worldwide [1], with the highest frequency observed in
Africa, Asia, the Mediterranean and the Middle-East [2-4].
G6PD deficiency is caused by one or more mutations in
the G6PD gene on chromosome X, which lead to func-
tional variants of the protein resulting in different bio-
chemical and clinical phenotypes. The most common
clinical manifestations are neonatal jaundice and acute
haemolytic anaemia, which in most patients is triggeredtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 PCR primer sequences, G6PD gene fragments amplified and PCR product sizes
Frag-ment Exon(s) Forward primer sequence (5’-3’) Reverse primer sequence (5’-3’) PCR product size
1 1,2 CAATAGGGCCGGCTTGAC TGCAACAATTAGTTGGAAAAGC 1376bp
2 3,4,5 TGTCCCCAGCCACTTCTAAC CTCATAGAGTGGTGGGAGCA 1125bp
3 6,7 AGGGGTTCAAGGGGGTAAC TGCAGGGTGACTGGCTCT 563bp
4 8 ACAGGGCGGGGAGCTAAG GTGCCTCGTCACAGATGG 202bp
5 9,10 CCTGAGGGCTGCACATCT GTGTCTTGCTGATGCCACTG 741bp
6 11,12,13 TGGCATCAGCAAGACACTCT GACAAGGAAGTGGGTCCTCA 1151bp
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jaundice is severe enough to cause death or permanent
neurological damage. In a proportion of cases, these mani-
festations may be life-threatening but fortunately, apart
from episodes of haemolytic anaemia, most G6PD-
deficient individuals are usually asymptomatic. A very small
proportion of G6PD-deficient individuals have chronic










0 Exon 3 153417565 T>C p
1 Exon 4 153417411 G>A p
2 Exon 5 153416686 A>G p.A
3 Exon 6 153415828 C>T p.
4 Exon 6 153415757 A>G p.
5 Exon 9 153414531 G>A p.
6 Exon 9 153414434 T>C p.
7 Exon 11 153413848 C>T p
8 Intron 153413702 T>C
11
9 Exon 12 153413666 G>A p.
10 Exon 12 153413623 C>T p.
11 Intron 153413340 -/GGA
13
12 Intron 153413052 A>G
13
Footnote to Table 2: *, locus designation used throughout this communication and
from G6PD reference sequence (UCSC Genome Browser, February 2006 build).G6PD activity is fatal. Because the disorder has an X-linked
recessive mode of inheritance, males are usually more se-
verely affected than females, though homozygosity, com-
pound heterozygosity, or skewed X-inactivation of affected
chromosomes may produce symptoms in females [5].
There are over 190 recorded G6PD gene mutations:
each has a characteristic distribution in different geo-




F (N) M (N)
Hom. Het. Hemi.
.Ile48Thr AURES 13 20 58
(86) (86) (163)
.Val68Met A- 4 8 20
(86) (86) (163)
sn126Asp A- 0 8 23
(86) (86) (163)
Ser188Phe MEDITERANEAN 9 20 36
(86) (86) (163)
Met212Val SIBARI 0 0 2
(86) (86) (163)
Val291Met VIANGCHAN 0 0 1
(86) (86) (163)
Leu323Pro A- 0 1 0
(86) (86) (163)
.Tyr437Tyr - 14 18 51
(61) (61) (102)
- - 32 18 77
(61) (61) (102)
Arg463His ANANT 1 0 3
(61) (61) (102)
Pro477Pro - 0 1 1
(61) (61) (102)
- - 0 2 1
(61) (61) (102)
- - 1 3 1
(61) (61) (102)
for the linkage disequilibrium analysis locus codes. ** Nucleotide numbers are
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is common and those where Plasmodium falciparum
malaria is endemic provides circumstantial evidence that
G6PD deficiency confers resistance against malaria [4].
The global distribution of mutations correlates with his-
torically recorded distributions of the disease [3,4,6-9].
To date, only one large scale systematic study of G6PD
gene mutations associated with G6PD deficiency has
been undertaken for the Saudi Arabian population, but
this study did not describe pan-gene G6PD haplotyping
nor sequencing of introns [10]. The aim of the present
study was therefore to sequence the G6PD gene in sus-
pected male and female G6PD-deficient patients from the
Saudi population and to determine the patterns of muta-
tion and polymorphism in cis (haplotypes) within the
gene by physical linkage analysis in male patients, and by
haplotype reconstruction in female patients. In addition,
the correlation between specific G6PD haplotypes and
the activity of G6PD was examined in all male patients,
and in female patients who were homozygous or hetero-
zygous for a given haplotype.
Methods
Patients
249 individuals with suspected G6PD deficiency were
selected based on clinical observation (163 male, 86 fe-
male). The individuals enrolled originated mostly from
the Western region of the Kingdom of Saudi Arabia.
Members of this cohort ages ranged from newborn to















1 T G A C
2 C G A C
3 T G A T
4 T G A C G
5 T G A C
6 T A G C
7 T A A C
8 T G G C
9 T A G T
10 T A A T
11 T G G T
12 C A A C
13 C G A T
Footnote to Table 3. (a) Haplotypes identified by 6-locus haplotyping. Non-conserva
right and correspond to loci 0–5, as designated in Table 1. Totals represent haploty
A-(1), A-(2) and A-(3) are variants of the A- phenotype [15]. (N)*=haplotype count.approved by the local Ethical Committee. All the indivi-
duals enrolled in this study were subjected to quantita-
tive measurement of their G6PD enzyme levels as well
as DNA extraction for G6PD mutational analysis.G6PD enzyme assay
Whole blood was used to quantitatively measure G6PD
enzyme activity using a UDICHEM-310 spectrophotom-
eter (United Diagnostics Industry, Damman, K.S.A).
G6PD activity was determined for all samples according
to WHO recommendations [11] using the UV/Kinetic
method (United Diagnostics Industry G6PD quantitative
kit 038–020, UDI, Dammam, K.S.A).G6PD gene PCR
Genomic DNA was extracted from whole blood and quan-
titated using standard methods (QIAamp DNA Blood Mini
kit, Qiagen). PCR primers were designed using Primer 3.0
software (http://frodo.wi.mit.edu/primer3/). A G6PD refer-






A G 76 43 NORMAL
A G 45 49 AURES
A G 34 29 MEDITERANEAN
G 0 2 SIBARI
A A 0 1 VIANGCHAN
A G 7 5 A-(1)
A G 6 5 A-(2)
A G 1 15 A-(3)
A G 0 1 JA
A G 2 2 JB
A G 0 2 JC
A G 1 7 JD
A G 0 1 JE
172 163 TOTAL
tive mutated bases are shown in bold. Mutant loci are numbered from left to
pes numbers, not patient numbers (except in males where these are identical).
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exons including associated intron-exon boundaries for the
entire coding region. The primer length was typically 18–
22 nucleotides with a GC ratio of about 50%. The specificity
of the PCR primers was ascertained by performing hom-
ology searches using the NCBI BLAST tool. Oligonucleo-
tides were synthesized by MWG Operon (Eurofins,
Germany). Sequences of the PCR primers are shown in
Table 1. Touchdown PCR reactions contained genomic
DNA (100 ng), PCR forward primer (10pmol), PCR reverse
primer (10pmol), dNTPs (10 mM), 0.5U Hot Start Taq
DNA polymerase (Qiagen, 5U/μL), 10 X PCR buffer
(Qiagen) containing 1.5 mM MgCl2 in a total volume of
25 μl. Samples were initially denatured at 95°C for 15 min.
DNA amplification was performed using 30 cycles of de-
naturation at 95°C for 30 sec, initial annealing starting at
70°C for 30 sec, and extension at 72°C for 30 sec. The
annealing temperature was reduced by 0.5°C at each subse-
quent cycle. Another 30 cycles of fixed annealing
temperature PCR was performed, starting by denaturation
at 95°C for 30 sec, annealing at 54°C for 30 sec and exten-
sion at 72°C for 30 sec. A final extension step at 72°C for
5 min was performed to allow the newly synthesized frag-
ments to complete replication. All PCRs were performed
using a Bio-Rad DNAThermal Cycler (Bio-Rad, USA).DNA sequencing
PCR products were ethanol-precipitated and subjected
to DNA sequencing using a BigDye Terminator v1.1/
v3.1 Cycle Sequencing Kit (Applied Biosystems), and anFigure 1 Patterns of Linkage disequilibrium of the G6PD variations as
and the shading of the boxes corresponding to D' values as shown in theApplied Biosystems automated DNA sequencer (ABI
PRISM Genetic analyzer 3130, Hitachi).
Genotype and haplotype analysis
Patient genotypes were assigned using BLAST alignment
with the G6PD reference genomic DNA sequence
NT_167198. All sequences matched the reference gen-
omic sequence except for mutation or polymorphism
sites at the loci shown in Table 2. Haplotypes in male
patients were evident since males are hemizygous for
the X chromosome. Haplotypes in female patients were
reconstructed using maximum likelihood analysis
(PHASE version 2.1) [12,13] with allowance for recom-
bination and decay of linkage disequilibrium with dis-
tance. Linkage disequilibrium between adjacent pairs of
mutant or polymorphic loci was determined by analysis
of the Lewontin's |D'| linkage disequilibrium coefficient,
using Haploview [14]. Unpaired t test is used for analys-
ing the effect of G6PD mutations on its enzyme activity.
Results
Mutations and polymorphisms identified in the patient
cohort, singly or in combination, are listed in Table 2.
Mutations were subsequently identified as components
of G6PD haplotypes by physical linkage or PHASE ana-
lysis as described. Comparisons of 6-locus G6PD haplo-
typing for both male and female patients are shown in
Table 3. 6-locus G6PD haplotypes were identifiable dir-
ectly because males are hemizygous for the X chromo-
some and therefore genotypes at each G6PD locus are in




























































































































Figure 2 (See legend on next page.)
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Figure 2 Hapotype-phenotype correlation of the G6PD gene. (A) correlation between G6PD haplotype and G6PD enzyme levels in male
individuals with G6PD mutation. (B) correlation between G6PD haplotype and G6PD enzyme levels in females.
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and revealed 13 haplotypes. The selection of the loci was
based upon extent of sequence coverage and the poten-
tial significance of the variation detected on protein
function. One haplotype was 'normal', that is, possessed
no amino acid substitutions in the region sequenced asso-
ciated with G6PD deficiency: this was observed in 43 male
patients (26.38%). In males, the three most common
pathogenic 6-locus haplotypes observed in order of fre-
quency were Aures, characterised by a single p.Ile48Thr
mutation (49/163, 30.06%), Mediterranean, characterised
by a single p.Ser188Phe mutation (29/164, 17.79%) and
variant of A- designated A-(1–3) [15] characterised by a
combination of p.Val68Met and p.Asn126Asp mutations
(25/163, 15.33%). Other haplotypes were each present
in less than 2% of male patients. However, 5 haplo-
types were previously unreported (Jeddah A, B, C, D
and E) and were all characterised by novel combina-
tions of two or three non-conservative amino acid
substitutions (Table 4). These novel haplotypes
accounted for 13/163 (7.97%) of the male patients
with Jeddah D (JD) being the most common novel
haplotype as it was detectable in 7/163 male patients
(4.29%).
G6PD haplotypes were identified in female patients
using PHASE haplotype reconstruction. 6-locus haplotyp-
ing was performed for 86 patients (172 haplotypes) and
revealed 8 haplotypes. In females, the two most common
pathogenic 6-locus haplotypes observed in order of fre-
quency were Aures, (45/172, 26.16%) and Mediterranean
(34/172, 19.76%). Other pathogenic haplotypes were
each present with a haplotype frequency less than 5%.
Only 2 of the novel Jeddah haplotypes were identified
in the female patients (Jeddah B and Jeddah D).
Haplotype data permitted the analysis of linkage dis-
equilibrium (LD) between pairs of adjacent mutant or
polymorphic loci beyond the 6-loci used for haplotype
analysis. As shown in Figure 1, the synonymous p.Tyr437-
Tyr and the T > C polymorphism in intron 11 exhibit a
LOD score of 10.23 and D’ value of 0.947. Significant link-
age disequilibrium exists between the p.Tyr437Tyr poly-
morphism and the p.Asn126Asp mutation (LOD= 2.53,
D’ = 0.769) or the p.Val68Met mutation (LOD= 3.04, D’ =
0.734). Significant linkage disequilibrium is also detect-
able between p.Ser188Phe and p.Ile48Thr (LOD = 2.93,
D’ = 1.0) and p.Asn126Asp with p.Val68Met (LOD=
21.03, D’ = 0.806), suggesting that several other haplo-
types can be detected if the synonymous changes or in-
tronic polymorphisms were to be included.Correlation between G6PD haplotype and G6PD enzyme
levels
Figure 2 and Tables 5–6 illustrate the effect of different
G6PD haplotypes on the level of G6PD expressed. The
dominant effect on expression of a given haplotype could
be assessed by analysing males who were hemizygous and
females who were homozygous for that haplotype, since
these individuals only possess the mutant haplotype. The
effect on expression of a given haplotype in heterozygous
females was also examined. In females who are carriers of
a mutant G6PD haplotype, mosaic expression of G6PD on
the affected X chromosome due to skewed X-inactivation
can lead to clinical G6PD deficiency.
Discussion
Our approach to a genetic analysis of G6PD deficiency
in the Saudi population was to identify haplotypes of
G6PD using a combination of DNA sequencing of exons
3, 4, 5, 6, 7, 9, 10, 11 and 12 and introns 11 and 13, uti-
lising physical linkage to define G6PD haplotypes in
male patients, and PHASE analysis to reconstruct haplo-
types in female patients. Definition of haplotype phase
in female patients who are compound heterozygotes (for
mutations or polymorphisms) can be addressed success-
fully using PHASE reconstruction of haplotypes, when a
suitably significant number of patients are available, as
was the case in our study. Haplotype analysis addresses
not only the distribution of pathogenic mutations, but
their linkage in cis with other pathogenic mutations and
polymorphisms, and thus permits linkage disequilibrium
analysis for any given gene. In this communication, we
report the results of a 6-locus haplotypic analysis of the
G6PD gene in Saudi patients suffering from G6PD defi-
ciency. 6-locus haplotyping identified 13 haplotypes in
males (1 normal, 12 pathogenic) and 8 in females (1 nor-
mal, 7 pathogenic). Extending the haplotype analysis loci
distal to exon 9 this resulted in only one further patho-
genic mutation being identified (Anant, Arg463His).
However it generates a significant amount of informa-
tion about polymorphic variants within the gene and
increased the total number of haplotypes observed. Ana-
lysis of pairwise linkage disequilibrium revealed signifi-
cant linkage patterns between specific pairs of loci.
To date, only a few previously published reports of
G6PD phenotype-genotype correlations have identified
genotypes that represent combinations of more than one
non-conservative mutation. Indeed, in a review by
Beutler & Vulliamy [15-17] only 10 of 140 non-conservative
amino acid mutations are combinations of more than one
Table 5 G6PD enzyme values according to haplotype in male patients
Males Normal Aures Med. A-(1) A-(2) A-(3) Sibari Viang. JA JB JC JD JE
N 43 49 29 5 4 15 2 1 1 2 2 7 1
Minimum 0.90 0.28 0.20 7.00 0.25 2.33 14.00 7.96 3.00 0.82 6.31 0.90 1.15
Maximum 361.00 118.20 198.00 9.00 218.00 292.70 20.84 7.96 3.00 9.00 8.43 21.00 1.15
Median 139.00 9.00 6.86 9.00 76.20 11.00 17.42 7.96 3.00 4.91 7.37 9.00 1.15
Mean 131.30 13.29 13.83 8.40 92.66 36.52 17.42 7.96 3.00 4.91 7.37 9.87 1.15
Std. Error 16.01 2.67 6.68 0.40 53.22 18.83 3.42 0.00 0.00 4.09 1.06 2.24 0.00
P-value <0.0001 <0.0001 0.012 0.425 0.002 - - - - - 0.003
P-values compared to normal G6PD levels.
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pathogenic G6PD haplotypes (Jeddah A through E),
all of which are represented by combinations of 2 or
3 non-conservative amino acid substitutions (Table 2).
Even allowing for the fact that these combinations are
rare in the Saudi population and may be rare in other
populations, this provides a significant insight into
the cumulative mutation process in the G6PD gene.
We examined the effect of G6PD haplotype on levels
of expression of G6PD in order to identify haplotypes
which conferred the greatest clinical burden to patients.
Our data supports the hypothesis that G6PD haplotypes
representing two or more non-conservative amino acid
mutations confer a greater reduction in G6PD expres-
sion than in haplotypes which only represent a single
non-conservative amino acid mutation. This is perhaps
unsurprising since the structure of the G6PD enzyme is
more abnormal in the former cases.
Identification of the novel Jeddah A, B, C, D and E haplo-
types could prove extremely important, since even carriers
of two or more non-conservative amino acid mutations ap-
pear to have clinically significant G6PD deficiency.
The advantages of a haplotypic analysis of the G6PD
gene is beyond doubt. We elected to pursue this ap-
proach to provide a wider viewpoint of G6PD genetics
than a study focussed on the detection of single muta-
tions. Detection of a given haplotype in males in our
study provided confidence that identification of that
haplotype in females represented confirmed linkage, not
a computational artifact of the PHASE analysis.Table 6 G6PD enzyme values according to haplotype in fema
Females Normal Aures (hom.) Aures (het.) Med. (hom.)
N 26 13 8 8
Minimum 31 0.018 5.9 0.939
Maximum 281 218 181.6 55
Median 120 9 70.77 9.05
Mean 138.9 26.62 77.5 13.16
Std. Error 13.87 16.21 18.77 6.193
P-value <0.0001 0.031 <0.0001
P-values compared to normal G6PD levels.Despite a significant effort in sequencing the G6PD gene
in our patient cohort, ‘normal’ G6PD haplotypes were
identified in 43 hemizygous male patients and in 26 female
patients who possessed two apparently ‘normal’ X chro-
mosomes. This may indicate the presence of a pathogenic
mutation situated outside the regions covered by our se-
quencing strategy which may affect G6PD expression, but
nonetheless our data is consistent with other studies [10]
in which no G6PD mutations have been detected.
The predominant G6PD haplotypes in our patient co-
hort represent previously reported Aures (p.Ile48Thr)
and Mediterranean (p.Ser188Phe) haplotypes. However,
this report represents the first complete haplotypic ana-
lysis of the G6PD gene in patients from Saudi Arabia.
We describe 5 previously unreported G6PD haplotypes
which are characterised by novel combinations of extant
mutations. These novel combinations pose interesting
questions as to the existence of, and interplay between,
putative mutation hotspots within the G6PD gene.
Conclusions
Over 400 million people worldwide suffer from a defi-
ciency of G6PD that results in mild to severe anaemia.
The deficiency is caused by a range of inherited genetic
mutations, but is most usually caused by a single muta-
tion in the G6PD gene. We have discovered 5 new
examples where more than one mutation exists in the
same gene. These mutations have been seen singly in
previous studies, but never in multiple combinations.
The effect of the multiple mutations is to produce ale patients
Med. (het.) A-(2) (hom.) A-(het.) JB (het.) JD (het.)
13 1 9 2 1
1.9 120 1.8 74 74
189.4 120 123 97.17 74
38.54 120 30 85.58 74
57.53 120 42.98 85.58 74
14.91 0 14.43 11.58 0
0.0008 - 0.0006 - -
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ity according to the number of accumulated mutations.
Females, who are normally only carriers of the disease,
are generally unaffected or only show mild deficiency.
However, our study suggests that females who possess
multiple mutations are more G6PD-deficient than car-
riers of single mutations. This observation adds further
complexity to G6PD deficiency testing as the severity of
the disease may also be determined by the position of
the mutation in the protein as some mutations may
affect the G6PD functional domains. Our study demon-
strates that during genetic testing, it is now important to
test for multiple mutations, since these are associated
with the severity of G6PD deficiency. Identification of
multiple mutations in patients could therefore be used
predictively to identify patients at risk of severe disease.
Competing interests
Some of the findings in this work are being considered for patent
application.
Authors’ contributions
AD and HB performed research, collected data, analyzed and interpreted
data, performed statistical analysis, and co-wrote the manuscript; MAG, MHA,
AMA, FA and AGC supplied samples, interpreted data and contributed vital
new reagents or analytical tools; WK and JB designed research, analyzed and
interpreted data, performed statistical analysis, and co-wrote the manuscript.
All authors read and approved the final manuscript.
Acknowledgements
This study was supported by research funding from The Centre of Excellence
in Genomic Medicine Research, King Abdul-Aziz University, to HB, MAG, JB
and WK.
Author details
1School of Cellular and Molecular Medicine, Medical Sciences Building,
University of Bristol, University Walk, Bristol BS8 1TD, UK. 2Center of
Excellence in Genomic Medicine Research, King Abdulaziz University, Jeddah,
Saudi Arabia. 3Department of Hematology, Faculty of Medicine, King
Abdulaziz University, Jeddah, Saudi Arabia.
Received: 3 July 2012 Accepted: 19 September 2012
Published: 24 September 2012
References
1. Minucci A, Concolino P, Vendittelli F, Giardina B, Zuppi C, Capoluongo E:
Glucose-6-phosphate dehydrogenase Buenos Aires: a novel de novo
missense mutation associated with severe enzyme deficiency. Clin
Biochem 2008, 41(9):742–745.
2. Mason P, Bautista J, Gilsanz F: G6PD deficiency: the genotype-phenotype
association. Blood Reviews. 2007, 21(5):267–283.
3. Cappellini M, Fiorelli G: Glucose-6-phosphate dehydrogenase deficiency.
Lancet 2008, 371(9606):64–74.
4. Frank J: Diagnosis and management of G6PD deficiency. Am Fam
Physician 2005, 72(7):1277–1282.
5. Orphanet Journal of Rare Diseases. 2010, 5:14. doi:10.1186/1750-1172-5-14.
6. Allison A: Glucose-6-phosphate dehydrogenase deficiency in red blood
cells of East Africans. Nature 1960, 186(4724):531–532.
7. Beutler E, Kuhl W, Vives-Corrons J, Prchal J: Molecular heterogeneity of
glucose-6-phosphate dehydrogenase A. Blood 1989, 74(7):2550–2555.
8. Ruwende C, Khoo á SC, Snow RW: Natural selection of hemi- and
heterozygotes for G6PD deficiency in Africa by resistance to severe
malaria. Natrue 1995, 376(6537):246–249.
9. May J, Meyer C, Groterlinden L, et al: Red cell glucose-6-phosphate
dehydrogenase status and pyruvate kinase activity in a Nigerian
population. Tropical Medicine & International Health. 2000, 5(2):119–123.10. Faiyaz U, Haque M, Zaidi S, Hasanato R, et al: Genetics of glucose 6
phosphate dehydrogenase deficiency in Saudi patients. Clin Genet 2010,
78(1):98–100.
11. Betke K, Beutler E, Brewer G, Kirkman H: Standardization of procedures for
the study of glucose-6-phosphate dehydrogenase. In Report of a WHO
scientific group, Volume 366. WHO Tech Rep; 1967.
12. Stephens M, Smith NJ, Donnelly P: A new statistical method for haplotype
reconstruction from population data. Am J Hum Genet 2001, 68(4):978–989.
13. Stephens M, Scheet P: Accounting for decay of linkage disequilibrium in
haplotype inference and missing-data imputation. Am J Hum Genet 2005,
76(3):449–462.
14. Reich D, Cargill M, Bolk S, et al: Linkage disequilibrium in the human
genome. Nature 2001, 411(6834):199–204.
15. Beutler E, Vulliamy T: Hematologically important mutations: Glucose-6-
phosphate dehydrogenase. Blood cells, molecules and diseases. 2002,
28(2):93–103.
16. Beutler E, Vulliamy T, Luzzatto L: Hematologically important mutations:
glucose-6-phosphate dehydrogenase. Blood Cells Molecules and Diseases.
1996, 22:49–56.
17. Vulliamy T, Luzzatto L, Hirono A, Beutler E: Hematologically important
mutations: glucose-6-phosphate dehydrogenase. Blood Cells Molecules
and Diseases 1997, 23:302–313.
doi:10.1186/1479-5876-10-199
Cite this article as: Dallol et al.: Five novel glucose-6-phosphate
dehydrogenase deficiency haplotypes correlating with disease severity.
Journal of Translational Medicine 2012 10:199.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
